TCR2 Shoots for $100 Million IPO in Early 2019

Cambridge, Mass.-based TCR2 Therapeutics is looking to secure $100 million in an initial public offering. Just before the end of 2018, the company filed its prospectus with the U.S. Securities and Exchange Commission, hoping that the new year will continue the IPO frenzy biotech enjoyed for much of 2018.